Tagged with RNA

Portugal Azevedos is one of the oldest pharmaceutical brands in Portugal. Lead by Thebar Miranda, president for 30 years it operates across Portuguese speaking companies and distributes worldwide. In this interview, Miranda highlights the importance of flexibility and high-quality in production and sheds light on global production trends, Portugal’s status as…

Ecuador Pablo Ledesma del Pozo, managing director at PharmaBrand, discusses the company’s ambition to equal the business model of a multinational companies in the foreseeable future by commercializing their products as well as opening fully-integrated affiliates in neighboring countries, such as Chile, Peru, Bolivia and Central American countries. Pablo, you have…

India Gaurav Aggarwal, Director of Lasons India Pvt Ltd and CEO of ‘OneLife’ the consumer division, highlights the key milestones of almost four decades in business that has helped them become a global exporters of Vitamin B3 (Niacin & Niacinamide). With passion, he also shares how he is committed to bring…

Baltics Vasily and Svetlana Bankovsky, founders of Biosan, talk about the company’s philosophy to develop modern, exciting personal products for sample preparation in the field of genomics, proteomics and cellomics and about their ambition to grow domestically and internationally. Vasily and Svetlana, can you give our international readers a brief overview…

Ecuador Francisco Cordero, general manager of Rocnarf, a proudly Ecuadorian family company with over 40 years of experience in the market discusses the company’s recent rebounding from experiencing severe price controls on its products. Looking forward, Cordero intends to develop international activities in collaboration with European, Middle Eastern and Central Asian…

Ecuador Efraim Lakierovich, general manager of Celsius in Ecuador, elaborates on the company’s recent internationalization, the unexpected challenges it has faced in the institutional market and his ambitions to grow the affiliate to the point that it surpasses the size of the Uruguayan headquarters. Could you tell our international readers about…

India Vinay Sapte, founder and managing director of Maneesh Pharmaceuticals, provides insights into this company’s unique development path. Maneesh was one of the first Indian companies to establish joint ventures in the US and Europe more than ten years ago and today stands as one of the largest India based partners…

Baltics Janis Biezbardis, chairman and owner of Latvian pharmaceutical wholesaler Farmeko, discusses the evolution of the company’s product portfolio, the receptiveness of the Latvian state to homegrown companies, and Farmeko’s international reach. Could you please start by telling us about the origins of your company? “The Latvian investment board and development…

India Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new…

Ecuador Hector Enriquez, general manager of Laboratorios Industriales Farmaceuticos Ecuadorianos (LIFE), details the flagship Ecuadorian pharmaceutical company’s focus on developing its own market-relevant formulations and the implementation of international manufacturing standards to compete with international pharmaceutical companies in Ecuador. Could you present LIFE Laboratories’ activities and most recent developments in Ecuador?…

Poland Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights Polpharma’s digital approach and the company’s long-term vision for sustained success across the region.   Our international markets are growing…

India Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on improving healthcare access and the cost of care. Against this…